Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Mahidol-Oxford Clinical Research Unit has been collaborating with the Indonesian Ministry of Health and the Menzies School of Health Research in Australia to conduct research on vivax malaria in Papua for many years.

The Eijkman-Oxford Clinical Research Unit (EOCRU) opened in 2008 within the Eijkman Institute of Molecular Biology (EIMB), situated on the large Salembacampus of the Faculty of Medicine University of Indonesia (FMUI) and CiptoMangunkusumo Hospital in Central Jakarta. EOCRU and its Indonesian hosts and partners collaboratively develop a research agenda of interest and relevance to Indonesian providers and their patients. Through more broadly relevant and high-impact clinical research endeavors, EOCRU deliberately cultivates technical capacities and people within Indonesia with the aim of fostering further independent clinical research. The direct access to patients suffering tropical and neglected infectious diseases allows the collaborative efforts to deliver tangibly better health outcomes for them. Previous or ongoing research include adjunctive dexamethasone therapy for TB meningitis patients living with HIV, hypnozoitocidal therapies for radical cure of Plasmodium vivax malaria, experimental live sporozoite vaccines against malaria, diagnostics for G6PD deficiency and CYP2D6 pharmacogenetics in connection with that therapy, mechanisms of primaquine hemolytic toxicity in G6PD-deficient patients, and assessment of automated malaria diagnostic instruments. Additionally, this unit investigates the impact of population mobility on malaria importation risks by applying big data cellphone-based geospatial analysis, quantifying burdens of morbidity and mortality of infectious and non-infectious diseases in relation to geography, socio-demography, and poverty in Indonesia.

Deeper Understanding and Better Health Outcomes

EOCRU has long focused on trials assessing the treatment of vivax malaria. Millions of cases of malaria occur in Indonesia each year, with about half of those caused by Plasmodium vivax. This species places dormant forms that awaken in people in the months following infection to cause repeated attacks of malaria. Arresting acute vivax malaria and preventing recurrent attacks requires treatment with two classes of drugs, one aimed at each. Assessing the safety and efficacy of the many possible combinations of such therapies ensures access to those treatments.

The therapeutics for Plasmodium vivax malaria includes two problems of human genetics: 1) hemolytic toxicity of the drug called primaquine in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; and 2) impaired metabolism of primaquine by natural polymorphism of cytochrome P-450 type 2D6 (CYP2D6). Primaquine is the only currently available drug effective against the dormant liver stages of P. vivax. Research at EOCRU takes aim at both of these issues in terms of diagnostics and understanding molecular mechanisms of these problems in order to ensure patients with vivax malaria are safely and effectively treated every time.

In 2017, EOCRU and FMUI jointly created the Universities of Indonesia and Oxford Clinical Research Laboratory (IOCRL) within the FMUI Department of Parasitology, with the aim of expanding its clinical research activities. New areas of interest include central nervous system infections, tuberculosis, HIV and antimicrobial resistance. TB meningitis, the most serious form of tuberculosisin patients living with HIV,is common in Indonesia. Aclinical trial of adjunctive dexamethasone therapy has been undertaken by EOCRU and its partners in striving to  improve the quality of life and survival of these patients. The global rise in drug-resistant infections, a consequence of antimicrobial usage and abuse, is one of the greatest public health challenges worldwide. In Indonesia, high-quality data on the burden and associated morbidity, mortality and economic cost of antimicrobial resistance are lacking. EOCRU aims to systematically study antibiotic access and usage, vital for developing biomedical and social interventions to curb drug-resistant infections.

Our team

Latest news

Asymptomatic individuals shown to transmit SARS-CoV-2 infection in Vietnam

Dr Le Van Tan in OUCRU, in collaboration with the Hospital for Tropical Diseases and the Department of Health, has shown that it is common for people who are infected with the virus that causes COVID-19 (SARS-CoV-2) to have no symptoms whatsoever. By testing quarantined people in Vietnam, his team was able to detect asymptomatic individuals. The virus disappeared faster from the bodies of the asymptomatic carriers than from that of symptomatic individuals, but it appeared that some of them still managed to pass the infection on to others.

How Vietnam managed to keep its coronavirus death toll at zero

Despite a long border with China and a population of 97 million people, Vietnam has recorded only just over 300 cases of Covid-19 and not a single death. The country very quickly enacted measures such as travel restrictions, monitoring and eventually closing border with China, closing schools and increasing health checks at borders and other vulnerable places. A vast and labour intensive contact tracing operation got under way. Quarantine on such a vast scale is key as evidence mounts that as many as half of all infected people are asymptomatic.

Sophie Yacoub nominated Emerging Leader in Infectious Diseases

In recognition of her past contributions to the field of international infectious diseases and in anticipation of her future impact on the discipline, Sophie Yacoub, Dengue Research Group Head at OUCRU, Ho Chi Minh City, Vietnam, is recognised as ISID Emerging Leader in International Infectious Diseases.

EOUCRU Research Highlights

Essential guidance on malaria elimination in its history

Posted 28/05/2019. Kevin Baird calls attention to the importance of local expertise in anopheline mosquito ecology as an essential weapon in striving to eliminate malaria. Slight but very specific modifications to environments that disfavour those mosquitoes achieved very significant gains before the advent of DDT insecticide and synthetic antimalarial commodities in the middle of the 20th century. Loss of those commodities, and a lack of alternative strategies, led to the great malaria resurgence of the latter 20th century.

HIV drug resistance in low-income and middle-income countries

Posted 02/10/2018. Rising prevalence of HIV drug resistance in low and middle-income countries poses a growing threat to the HIV response. To curb resistance, enhanced strategies are needed that improve quality of ART care and treatment. Raph Hamers reviews contemporary data and highlights the potential impact and resistance risks of novel ART strategies and knowledge gaps.

Picturing health: making malaria visible in Asia-Pacific

Posted 07/04/2017. Collaboration between photographer Pearl Gan and Professor Kevin Baird from our EOCRU unit in Jakarta, Indonesia, this photographic project aims to raise public awareness of malaria as a serious health problem for the region by telling the human story of Asia’s invisible malaria burden.